Udac, Raiven L.

HRN: 26-72-49  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/17/2025
CEFTRIAXONE 1G (VIAL)
02/17/2025
02/23/2025
IV
580
Q24
PCAP C
Waiting Final Action 
02/18/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
02/18/2025
02/24/2025
IV
40
Q12
PCAP C
Waiting Final Action 
02/19/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
02/19/2025
02/25/2025
IV
400 Mg
Q8H
PCAP C
Waiting Final Action 
02/20/2025
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
02/20/2025
02/27/2025
PO
1ml
TID
Oral Sores
Waiting Final Action 
02/20/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
02/20/2025
02/27/2025
IV
170mg
Q8
PCAP C
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: